Navigation Links
Halozyme Therapeutics Announces Public Offering of Common Stock
Date:9/8/2010

free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the public offering) that involve risk and uncertainties that could cause actual results to differ materiall
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... 26 Brainlab announced the availability of ExacTrac® Infrared Monitoring, ... during radiation therapy treatments, at the American Association of Physicists in ... , , ... tool used by many cancer care centers for patient setup; however, ...
... ,, ROCKVILLE, Md. , July 26 Sequella, Inc., ... announced today the publication of studies in the scientific journal Antimicrobial ... for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: ... Reddy, V.M., L. ...
Cached Medicine Technology:Brainlab Offers Real-Time Monitoring for IGRT 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 3
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
(Date:7/24/2014)... the risk for head and neck cancer (HNC). Evidence suggests ... the risk of HNC in patients with DM has not ... sixth most common type of cancer. It accounts for about ... new cancer cases and 350,000 cancer deaths worldwide each year. ... to examine the risk of HNC in patients with DM. ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3
... -- Despite growing concern about the effects of media ... to be produced and marketed to them. An Indiana ... to their enjoyment of such programs and their characters. ... Media Psychology , Andrew J. Weaver, an assistant ...
... Wong, one of the nation,s foremost experts on aging, ... on Aging of the National Institutes of Health to ... the grant for a longitudinal aging study she and ... will collect current data from thousands of participants and ...
... primary language is not English, patient navigators may help improve ... the May 23 issue of Archives of Internal Medicine ... of the journal,s Health Care Reform series. According to ... country,s main causes of cancer deaths. "Nevertheless," the authors write, ...
... -- New research suggests that a certain class of drugs ... risk that male patients will be unable to urinate. ... blockage in the body,s air passages, affects an estimated 10 ... class of drugs called "inhaled anticholinergic" medications are used to ...
... 2011More than eight of 10 leaders in health and ... to implement key provisions of the Affordable Care Act ... outlined in the law. Such key provisions include expanding ... insurance exchanges with premium subsidies. Findings are from the ...
... MONDAY, May 23 (HealthDay News) -- U.S. researchers have ... diseases, which are rare, progressive conditions that affect brain ... and bovine spongiform encephalopathy, commonly known as "mad cow ... of the Journal of the American Dietetic Association ...
Cached Medicine News:Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 2Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 3Health News:UTMB researcher receives $3 million NIH grant to study aging in Mexico 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 3Health News:Certain COPD Meds Linked to Urinary Troubles in Men 2Health News:States should be allowed to implement key health reform law provisions early, experts say 2Health News:States should be allowed to implement key health reform law provisions early, experts say 3Health News:CDC Warns Against Exposure to 'Mad Cow'-Like Brain Diseases 2
... fume containment system is ... equipment. Even large benchtop ... the Hyperclean 2. The ... unit comes complete with one ...
Reusable shielded cable...
... OIA test features a dual-detection technology to ... for children under age 5 with a ... in just over 15 minutes. This combination ... to decrease costs for unnecessary ancillary testing, ...
... OIA A/B test combines performance equivalence to 14-day ... A or B with a simple, easy-to-use test ... test has all the same procedural steps as ... enable you decrease costs for unnecessary ancillary testing, ...
Medicine Products: